AN2 Therapeutics develops therapies for rare, chronic, and serious infectious diseases using their boron chemistry platform. Self-described as having a pipeline of novel boron-based compounds.

AN2 Therapeutics

AN2 Therapeutics | 1,734 followers on LinkedIn. Developing therapies for rare, chronic, and serious infectious diseases | AN2 Therapeutics, Inc. is a biopharmaceutical company dedicated to developing therapies to treat rare, chronic, and serious infectious diseases in areas of high unmet needs.  Founded by a team of experienced industry leaders in infectious disease drug research and development and boron chemistry, we have a passion for addressing the challenges of infectious disease and improving global human health.   For more information, please visit www.an2therapeutics.com.

Sanjay Chanda

Executive Director, Clinical Operations

Kevin O'Shea

CEO & Co-Founder at AN2 Therapeutics

Eric Easom

Chief Financial Officer | Board Member

Stephanie Wong

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

AN2 Therapeutics supports the companionship that pets provide. Earlier this week we welcomed Taiko, Hiero, Niall, Blue, Piper, Peanut, Lizzie, and Elroy to our offices in Menlo Park.

Back from #ATS2024 ! We’re excited to have connected with healthcare professionals and clinicians supporting patients with rare, chronic and serious pulmonary diseases. #ATS

April 14 is #WorldChagasDay . We take this important opportunity to draw attention to this neglected disease that affects ~6 to 7 million people globally. We are proud to advance our preclinical drug candidate AN2-502998 (formerly AN15368) as a potential new treatment for patients with #ChagasDisease .

Today is #WorldNTDDay , a day where we raise awareness for the neglected tropical diseases that affect the world’s most vulnerable populations. At AN2 we have a passion for addressing the challenges of infectious diseases and improving global human health. #WorldNTDDay #research #Chagas #neglectedtropicaldiseases

jQuery CDN

Mobile Optimized

Drupal

Adobe Dynamic Tag Management

Drupal 10

Akamai EdgeWorkers

Akamai EdgeConnect

CEO & Co-Founder

Chief Legal Officer

Joshua Eizen

Chief Medical Officer

Paul Eckburg

Vice President Quality Assurance

Alexander Tung

Senior Vice President Regulatory Affairs and Quality

Jennifer Huber

Vice President | Drug Development & CMC

Kieron Wesson

Vice President of Chemistry

Vince Hernandez

Information Technology

Bibiana C.

Senior Director Program Management

Kate Stuart

Patricia Martin

Joseph Zakrzewski

Founder, Investor & Board Member

Chief Development Officer

MIchael Alley

Co-Founder & Head of Biology

George Talbot

Co-Founder & Clinical Advisor to the Board

United States Public Companies With Less Than $10M in Revenue

Companies With Less Than $1M in Revenue (Top 10K)

San Francisco Bay Area Companies With Fewer Than 1000 Employees (Top 10K)

Biotechnology Companies (Top 10K)

AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases.

The company was founded in 2017 and is headquartered in Menlo Park, California, United States.

Bill & Melinda Gates Foundation

Grant - AN2 Therapeutics

Post-IPO Equity - AN2 Therapeutics

RA Capital Management

Series B - AN2 Therapeutics

Mountain Group Capital

Series A - AN2 Therapeutics

Menlo Park

California

United States

North America

North American Morning Briefing : Russia's Nuclear -2-

AN2 Therapeutics to Meet With FDA on Epetraborole Development Path

AN2 Therapeutics Plunges 66% in a Month: Here's Why

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics shares target cut by Evercore ISI on delayed trial data

An oral treatment being developed for chronic non-tuberculous mycobacterial (NTM) lung disease, specifically targeting Mycobacterium avium complex (MAC).

A research and development approach utilizing boron chemistry to create novel compounds for treating infectious diseases.

Conducting studies to gain regulatory approval for new medications aimed at treating infectious diseases.

Philippines

Asia

Bangladesh

Indonesia

Mexico

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

AN2 Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 19, 2024 6:03 AM	24263218
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 6:03 AM	f1c07a5f
crunchbase trigger	general	Nov 19, 2024 6:03 AM	b3a74339
crunchbase profile	general	Nov 19, 2024 11:44 PM	4dea62b7
li profile	general	Nov 19, 2024 6:03 AM	d94aad80
translate crunchbase fundingrounds	general	Nov 20, 2024 12:30 AM	5a5a68d1
peers	general	Nov 19, 2024 6:03 AM	156f1818
news basic	general	Nov 19, 2024 6:03 AM	2ca99fca
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AN2THERAPEUTICS

AN2 Therapeutics

Last Close

1.23

22/11 21:00

Market Cap

77.56M

Beta: -

Volume Today

1.25M

Avg: -